Immix Biopharma
Developing BCMA-targeted CAR-T therapy for relapsed or refractory AL amyloidosis.
Something off on this page? Send us feedback.
Profile
Develops investigational therapies led by NXC-201, a BCMA-targeted CAR-T candidate for relapsed or refractory AL amyloidosis. The pipeline also includes the earlier IMX-110 solid-tumor program, while clinical progress depends on trial execution, future data, regulatory review, manufacturing, and continued financing.
Develops investigational cell therapies and tissue-specific therapeutics for serious diseases. The lead program, NXC-201, is a BCMA-targeted CAR-T candidate being studied in relapsed or refractory AL amyloidosis, while IMX-110 remains the earlier solid-tumor program.
Clinical work spans the U.S. NEXICART-2 study and the ex-U.S. NEXICART-1 study. Development has shifted from the original solid-tumor platform toward NXC-201, brought into the portfolio through an exclusive license and integrated through Nexcella.
NXC-201 remains investigational. Progress depends on completing clinical studies, producing future data, securing regulatory review, maintaining manufacturing, and raising capital to fund development.
Company facts
Key statistics
Year to date +156% · Average volume (30d) 1.7M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 11, 2026 | Morgan Stanley | Reiterate | Overweight | $19 | |
| Aug 10, 2026 | H.C. Wainwright | Reiterate | Buy | $20 | $25 |
| Jul 22, 2026 | Needham | Initiate | Buy | ||
| Jun 18, 2026 | Citigroup | Initiate | Buy | ||
| May 22, 2026 | H.C. Wainwright | Target | $15 | $20 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 7, 2026Q2 FY26 | −$0.17 | −$0.18 | −5.9% | — | — | — | −3.38% |
| May 7, 2026Q1 FY26 | −$0.18 | −$0.18 | +0.3% | — | — | — | +2.20% |
| Mar 25, 2026Q4 FY25 | −$0.21 | −$0.27 | −28.6% | — | — | — | −2.13% |
| Nov 7, 2025Q3 FY25 | −$0.19 | −$0.24 | −26.3% | — | — | — | +2.86% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $0 | |
| Operating income | −$4.7M | −$6.7M | −$7.7M | −$10.9M | −$10.8M | −$12.5M | |
| Net income | −$4.5M | −$6.6M | −$7.6M | −$10.7M | −$10.1M | −$11.6M | |
| Diluted EPS | −$0.15 | −$0.22 | −$0.24 | −$0.28 | −$0.18 | −$0.18 | |
| Gross margin | — | — | — | — | — | — | |
| Operating margin | — | — | — | — | — | — |
Fiscal years (4-quarter sums)FY21 $0 · FY22 $0 · FY23 $0 · FY24 $0 · FY25 $0
Balance sheet, Jun 30, 2026Cash & short-term investments $232.1M · Total debt $1.0M · Total assets $239.1M · Shareholders' equity $228.9M
Dividends
No dividends on record.
Ownership
Shares outstanding 54.40M · Float 43.40M · 79.8% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Janus Henderson Group PLC | 9.09M | 13.00% | 13G | Jun 5, 2026 |
| Eventide Asset Management, LLC | 3.89M | 5.60% | 13G | Aug 14, 2026 |
| Saturn V Capital Management LLC | 3.69M | 6.79% | 13F | May 15, 2026 |
| Vanguard Capital Management LLC | 1.79M | 3.29% | 13F | May 15, 2026 |
| Millennium Management LLC | 1.75M | 3.22% | 13F | May 15, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Dec 10, 2025 | Gabriel S. Morris | director, officer: CFO | +770 | $6.58 |
| Dec 10, 2025 | Ilya M. Rachman | director, officer: CEO and Chairman | +746 | $6.67 |
| Sep 16, 2025 | Gabriel S. Morris | director, officer: CFO | +2,600 | $1.97 |
| Sep 17, 2025 | Ilya M. Rachman | director, officer: CEO and Chairman | +2,500 | $2.02 |
Peers
- AbbVie
Closest pipeline overlap in relapsed/refractory AL amyloidosis
- Johnson & Johnson
Approved AL standard and broad BCMA portfolio across plasma-cell disease
- Pfizer
BCMA bispecific overlap in relapsed/refractory AL amyloidosis
- AstraZeneca (ADR)
Anti-fibril program pursuing a narrower path in advanced AL amyloidosis
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Immix Biopharma | $13.82 | −0.72% | $758.4M | — | — | — | — |
| AbbVie | $255.80 | +0.13% | $451.38B | 72.0 | 16.8 | 7.0 | +10.2% |
| Johnson & Johnson | $268.40 | +0.13% | $645.95B | 31.1 | 22.4 | 6.6 | +6.6% |
| Pfizer | $27.95 | −0.04% | $159.36B | 36.9 | 10.0 | 2.5 | +2.6% |
| AstraZeneca (ADR) | $161.79 | −0.55% | $252.33B | 24.4 | 15.2 | 4.1 | +6.4% |
| Median | 34.0 | 16.0 | 5.3 | +6.5% |